It has been hypothesized that metalloproteinases, and particularly MMP3, could a have a role in degrading anti–tumor necrosis factor drugs, leading to treatment failure in patients with inflammatory bowel disease (IBD).
Activated metalloproteinases degrade both matrix and nonmatrix proteins, and play a key role in wound healing, tissue repair, and response to injury. When dysregulated, they can also have a role in the progression of inflammatory diseases and malignancies.
It has been hypothesized that these metalloproteinases, and particularly MMP3, could a have a role in degrading anti—tumor necrosis factor (anti-TNF) drugs, leading to anti-TNF failure in patients with inflammatory bowel disease (IBD).
Now, research presented at the 14th Congress of the European Crohn’s and Colitis Organisation finds that, after induction with infliximab, high MMP3 levels predicted a loss of response among patients with IBD over the coming 12 months.
In the study, the investigators retrospectively reviewed the data of 73 patients with IBD, 37 of whom had ulcerative colitis and 36 of whom had Crohn disease. Among the 73 patients, 37 had responded to anti-TNF therapy with infliximab after 52 weeks, and 36 had not responded.
All patients had their MMP3 tested at baseline, after induction, and again at 1 year. Trough levels and antidrug antibodies (ADAs) were also recorded at 1 year. The investigators also sampled the MMP3 levels of 28 healthy volunteers as controls.
They found that, between responders and nonresponders to infliximab, serum levels at baseline were not significantly different. However, after induction, responders had levels of 8.68 ng/ml while nonresponders had levels of 25.7 ng/ml (P <.001). At 12 months, these values were 11.63 ng/ml and 29.72 ng/ml, respectively (P <.001).
Furthermore, among nonresponders with low trough levels, those who had high ADA levels and those who had no ADAs had similar MMP3 levels (32.01 and 24.56, respectively, P = .1), and there was a significant negative correlation between MMP3 levels and trough levels at 1 year in the overall population.
According to the authors, high MMP3 levels post-induction predict loss of response over the next year, and patients who are nonresponders to infliximab, regardless of ADAs, demonstrate high MMP3 levels.
Reference
Barberio B, D’Inca R, Facchin S, et al. Mechanisms of infliximab failure: the predictive role of MMP3. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P650.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.